Velsera and Solaris Health have collaborated to expand access to genetic testing in the US to help urology patients understand cancer risks.
Solaris Health affiliates that are using the Genetic Interpretation and Clinical Reporting Platform of Velsera will provide inherited cancer testing through their labs to improve patient care.
The partnership involves linking the genetic sequencing platform in the practice group’s laboratory to Velsera’s Clinical Genomics Workspace (CGW) platform used for genetic analysis and patient reporting.
CGW utilises the sequencing output to offer tools for generating clinical interpretations and reports that are ready for physicians, thereby enabling a better focus on clinical management and patient care.
The CGW platform, in combination with Velsera’s expert professional services, provides a complete solution for physician practises who either own a lab or aspire to establish one.
This solution is suitable for those lacking the necessary resources or in-house expertise to independently implement and oversee large-scale genomic testing.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
The collaboration with Velsera has advanced the objective of making guideline-based testing more widely accessible nationwide, according to Solaris Health.
Velsera chief medical officer Rakesh Nagarajan said: “This collaborative relationship shows what’s possible for physician-owned labs that are looking to offer or expand cutting-edge genomics-based care.
“Whether in urology or in other specialities, improving the diagnosis of multiple types of cancer and inherited genetic disease by bringing NGS-based genomic testing in-house is now more attainable than ever.”